Monograph Details
|
|
Poisoning & Drug Dependence
> Poisoning/overdose
|
|
EXJADE |
| Manufacturer |
|
Novartis Pharmaceuticals Corp |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Iron chelating agent. |
| Generic Name |
|
Deferasirox 125mg, 250mg, 500mg; tabs for oral susp. |
| Indications |
|
Chronic iron overload due to blood transfusions in patients ≥2 yrs of age. |
| Adults and Children |
|
Take on empty stomach. Do not chew or swallow tabs; disperse completely in water, orange juice or apple juice; drink immediately; resuspend remainder and drink. <2yrs: not recommended. ≥2yrs: initially 20mg/kg once daily; may adjust dose by 5 or 10mg/kg every 3 to 6 months based on serum ferritin levels or response; max 30mg/kg per day. Adjust dose if severe skin rashes occur; consider suspending therapy if serum ferritin <500mcg/L. |
| Precautions |
|
Do baseline auditory and ocular exams, then every 12 months; if disturbances occur, adjust dose or suspend therapy. Hepatic or renal impairment. Do baseline blood counts, serum creatinine, liver function, proteinuria, serum ferritin levels, then monitor monthly thereafter or during dose adjustments. Elderly. Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
Avoid aluminum-containing antacids. Other concomitant iron chelation therapy: not recommended. |
| Adverse Reactions |
|
GI upset, abdominal pain, pyrexia, headache, cough, elevated serum creatinine or serum transaminases (adjust dose; see literature), rash. |
| How Supplied |
|
Tabs—30 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
